Dysregulated FOXM1 signaling has been identified in a wide range of cancers including pancreatic cancer (Pilarsky et al., 2004), and this dysregulation is considered as a key regulator of EMT and CSC‐like properties (Chiu et al., 2015). Here, FOXM1 is linked to cancer.